222

MEDIAN DIAGNOSTICS

No trades
See on Supercharts

233250 fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Median Diagnostics Inc. engages in the manufacture and supply of in vitro diagnostic products for animal diseases and raw materials for human disease diagnosis. It operates through the following business divisions: Immunodiagnosis, Microbiological diagnosis, Molecular Diagnostics, Clinical chemistry tests, Blood test, and Urine test. The Immunodiagnosis division uses fluorescent labels, enzymes, and other chemical indicators to detect and quantify the analyte. The Microbiological diagnosis division includes identification of bacterial pathogens, virus culture and isolation, and antibiotic susceptibility testing. The Molecular Diagnostics division offers tests for unique nucleic acid sequences. The Clinical Chemistry tests division examines the health of companion animals. The Blood test division deals with the analysis of infections, inflammation, immunodeficiency, anemia, leukemia and other hematological disorders in animals. The Urine test division handles conditions including liver disease, kidney disease and dysfunction, diabetes, infections and other potential diseases. The company was founded on October 18, 1999 and is headquartered in Chuncheon-si, South Korea.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

233250 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company